Designing and testing new intervention therapies for lung cancer and mesothelioma

Published: 18-08-2010
Last updated: 10-08-2024

The aim of this study is to design and test new intervention therapies on tumorcells or tumorsamples on there sensitivity for several new drugs. Last few years there are a lot of new drugs available for cancer and have to be tested on there...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Respiratory and mediastinal neoplasms malignant and unspecified
Study type	Observational invasive

Summary

ID

NL-OMON34325

Source
ToetsingOnline

Brief title
New intervention therapies for lung cancer and mesothelioma

Condition

- Respiratory and mediastinal neoplasms malignant and unspecified

Synonym
lungcancer, mesothelioma

Research involving
Human

Sponsors and support

Primary sponsor: Antoni van Leeuwenhoek Ziekenhuis
Source(s) of monetary or material Support: KWF

Intervention

Keyword: lung cancer, mesothelioma, new intervention, therapies

Outcome measures

Primary outcome

Validate the findings of mouse-models in human tumor samples using pre-and

post-treatment surgical specimen and by studying

the response/resistance of primary explants of human tumors.

Secondary outcome

NA

Study description

Background summary

Lung cancer and mesotheliomas belong to the most devastating cancers with an extremely poor prognosis. The different lung cancer types and mesotheliomas arise from different cell types of the lung. They cause yearly over 9.000 deaths only in The Netherlands. The overall 5-year survival is less than 15%. With the development of drugs that inhibit specific components of signaling pathways known to be defective in these cancers, modest survival advantages have been achieved recently. However, genetic instability, an inherent feature of these tumors, almost invariably leads to escape by either mutations in the therapeutic target or activation of bypass signaling pathways. Understanding in detail these mechanisms of escape will be critical to improve the treatments of patients with these cancers. Reliable model systems that reproduce both genotypic and phenotypic characteristics of these cancers is an essential step in developing more effective combination therapies.

Study objective

The aim of this study is to design and test new intervention therapies on tumorcells or tumorsamples on there sensitivity for several new drugs. Last few years there are a lot of new drugs available for cancer and have to be tested on there effectiveness. With this research we hope that we can quickly make a good choice which drugs can be tested at patients.

Study design

Extra tumorsample will be sampled during research of the diagnosis or treatment of the disease. Further research will be done on the extra tumorsamples (on SCID mice)

Study burden and risks

The performance of an investigation gives always some risks. This is dependent on the kind of investigation. The time needed to take some tumor sample will differ from some seconds to a few minutes and will only be done on the responsibility of the physician. That's why the risk of taking a tumor sample will be minimal.

Contacts

Public
Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121
1066 CX Amsterdam
NL
Scientific
Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121
1066 CX Amsterdam
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Histologically proven lungcancer (SCLC or NSCLC) or mesothelioma

Exclusion criteria

Other malignant tumor than lungcancer or mesothelioma

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Diagnostic

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	30-08-2010
Enrollment:	80
Type:	Actual

Ethics review

Approved WMO

Date:	18-08-2010
Application type:	First submission
Review commission:	PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL32206.031.10